Catabasis Pharmaceuticals to Present at the Upcoming 2020 Solebury Trout Virtual Investor Conference
March 25 2020 - 8:00AM
Business Wire
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage
biopharmaceutical company, today announced that Jill C. Milne,
Ph.D., Chief Executive Officer, plans to present a corporate
overview and provide a business update at the upcoming Solebury
Trout Virtual Investor Conference on Tuesday, March 31, 2020 at
12:30pm EDT.
A webcast of the presentation will be available in the investors
section of the Company’s website www.catabasis.com, and will be
archived for 30 days following the presentation.
About Catabasis
At Catabasis Pharmaceuticals, our mission is to bring hope and
life-changing therapies to patients and their families. Our lead
program is edasalonexent, an NF-kB inhibitor in Phase 3 development
for the treatment of Duchenne muscular dystrophy. For more
information on edasalonexent and our Phase 3 PolarisDMD trial,
please visit www.catabasis.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200325005033/en/
Investor and Media Contact Andrea
Matthews Catabasis Pharmaceuticals, Inc. T: (617) 349-1971
amatthews@catabasis.com
Catabasis Pharmaceuticals (NASDAQ:CATB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Catabasis Pharmaceuticals (NASDAQ:CATB)
Historical Stock Chart
From Sep 2023 to Sep 2024